Compound Index
IGF-18Hexarelin5Selank4GHRP-24NMN / NR / NAD+ Precursors4BPC-1573TB-5003Ipamorelin3CJC-1295 (DAC)3CJC-1295 / Ipamorelin3CJC-1295 No DAC3Sermorelin3MK-6773Semaglutide3Tirzepatide3Retatrutide3AOD-96043GHK-Cu3Epitalon3Semax3NAD+3PT-1413Melanotan II3Thymosin Alpha-13LL-373MOTS-c3SS-31 (Elamipretide)3Tesamorelin3DSIP3Kisspeptin3
Metabolic11 min read
GLP-1 Agonists and Appetite Regulation: Hypothalamic Circuits, Ghrelin, and Hunger Endpoint Study Design
A mechanistic deep dive into how GLP-1 agonists suppress appetite through hypothalamic ARC/VMH circuits, ghrelin/GLP-1 axis interplay, gastric emptying, and reward pathway modulation — with validated hunger endpoints and study design for preclinical metabolic research.
May 31, 2026Read
Research Fundamentals11 min read
GLP-1 Agonist Discontinuation: Rebound Pharmacology, Washout Design, and Re-initiation Research Protocols
A comprehensive research guide covering the biological mechanisms of weight regain after GLP-1 agonist discontinuation, published clinical and preclinical rebound data, optimized washout period design, and re-initiation protocol strategies for researchers.
May 31, 2026Read
Compound Profiles11 min read
Retatrutide: Hepatic, Cardiac, and CNS Mechanisms Beyond Weight Loss
A deep dive into retatrutide's triple GLP-1R/GIPR/GCGR agonism effects on liver fat, cardiovascular endpoints, and brain circuits — mechanisms that extend far beyond the Phase 2 weight-loss headline data.
May 30, 2026Read